Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
Lexaria, a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for potential diabetes and weight loss treatment The company hopes to make these drugs more effective with reduced side effects, and even more accessible to people living with diabetes The move is aimed to help the company partner with the behemoths in an industry projected to bring in between $150 billion and $200 billion a year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is evaluating the impact of its patented DehydraTECH(TM) technology…